About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Reset

Showing: ticker LLY · Everything

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
Oct 9, 2026OLUMIANT
BARICITINIB
LLY
Eli Lilly and Co
New drug (NDA), supplement
Efficacy
NDA207924 ↗
Sep 25, 2026OLUMIANT
BARICITINIB
LLY
Eli Lilly and Co
New drug (NDA), supplement
Efficacy
NDA207924 ↗
Sep 23, 2026ONSWIK
INSULIN EFSITORA ALFA-GOBE
LLY
Eli Lilly and Co
Biologic (BLA)
Type 1 - New Molecular Entity
BLA761408 ↗
Sep 18, 2026INLURIYO
IMLUNESTRANT TOSYLATE
LLY
Eli Lilly and Co
New drug (NDA), supplement
Efficacy
NDA218881 ↗
Sep 18, 2026VERZENIO
ABEMACICLIB
LLY
Eli Lilly and Co
New drug (NDA), supplement
Efficacy
NDA208716 ↗
Aug 27, 2026MOUNJARO, MOUNJARO KWIKPEN
TIRZEPATIDE
LLY
Eli Lilly and Co
New drug (NDA), supplement
Efficacy
NDA215866 ↗
Aug 27, 2026MOUNJARO, MOUNJARO KWIKPEN
TIRZEPATIDE
LLY
Eli Lilly and Co
New drug (NDA), supplement
Efficacy
NDA215866 ↗
Aug 26, 2026ZEPBOUND, ZEPBOUND KWIKPEN
TIRZEPATIDE
LLY
Eli Lilly and Co
New drug (NDA), supplement
Efficacy
NDA217806 ↗
Aug 4, 2026FOUNDAYO
ORFORGLIPRON CALCIUM
LLY
Eli Lilly and Co
New drug (NDA), supplement
Labeling
NDA220934 ↗
Aug 3, 2026TERIPARATIDE, FORTEO
TERIPARATIDE
LLY
Lilly
New drug (NDA), supplement
Labeling
NDA021318 ↗
Jul 14, 2026RETEVMO
SELPERCATINIB
LLY
Eli Lilly and Co
New drug (NDA), supplement
Efficacy
NDA218160 ↗
Jul 14, 2026RETEVMO
SELPERCATINIB
LLY
Eli Lilly and Co
New drug (NDA), supplement
Efficacy
NDA213246 ↗
Jul 13, 2026VERZENIO
ABEMACICLIB
LLY
Eli Lilly and Co
New drug (NDA), supplement
Efficacy
NDA208716 ↗
Jun 30, 2026OLUMIANT
BARICITINIB
LLY
Eli Lilly and Co
New drug (NDA), supplement
Labeling
NDA207924 ↗
Jun 29, 2026STRATTERA
ATOMOXETINE HYDROCHLORIDE
LLY
Lilly
New drug (NDA), supplement
Labeling
NDA021411 ↗
Jun 9, 2026EBGLYSS
LEBRIKIZUMAB-LBKZ
LLY
Eli Lilly and Co
Biologic (BLA), supplement
Efficacy
BLA761306 ↗
Jun 5, 2026EMGALITY
GALCANEZUMAB-GNLM
LLY
Eli Lilly and Co
Biologic (BLA), supplement
Labeling
BLA761063 ↗
Apr 1, 2026FOUNDAYO
ORFORGLIPRON CALCIUM
LLY
Eli Lilly and Co
New drug (NDA)
Type 1 - New Molecular Entity
NDA220934 ↗
Mar 12, 2026TRULICITY
DULAGLUTIDE
LLY
Eli Lilly and Co
Biologic (BLA), supplement
Labeling
BLA125469 ↗
Feb 25, 2026ZEPBOUND, ZEPBOUND KWIKPEN
TIRZEPATIDE
LLY
Eli Lilly and Co
New drug (NDA), supplement
Labeling
NDA217806 ↗
Jan 20, 2026ZEPBOUND, ZEPBOUND KWIKPEN
TIRZEPATIDE
LLY
Eli Lilly and Co
New drug (NDA), supplement
Labeling
NDA217806 ↗
Jan 20, 2026MOUNJARO, MOUNJARO KWIKPEN
TIRZEPATIDE
LLY
Eli Lilly and Co
New drug (NDA), supplement
Labeling
NDA215866 ↗
Jan 7, 2026ZEPBOUND, ZEPBOUND KWIKPEN
TIRZEPATIDE
LLY
Eli Lilly and Co
New drug (NDA), supplement
Manufacturing (CMC)
NDA217806 ↗
Jan 7, 2026MOUNJARO, MOUNJARO KWIKPEN
TIRZEPATIDE
LLY
Eli Lilly and Co
New drug (NDA), supplement
Manufacturing (CMC)
NDA215866 ↗
Dec 19, 2025MOUNJARO, MOUNJARO KWIKPEN
TIRZEPATIDE
LLY
Eli Lilly and Co
New drug (NDA), supplement
Efficacy
NDA215866 ↗
Nov 25, 2025HUMATROPE
SOMATROPIN
LLY
Lilly
Biologic (BLA), supplement
Labeling
BLA019640 ↗
Nov 20, 2025RETEVMO
SELPERCATINIB
LLY
Eli Lilly and Co
New drug (NDA), supplement
Efficacy
NDA218160 ↗
Nov 20, 2025RETEVMO
SELPERCATINIB
LLY
Eli Lilly and Co
New drug (NDA), supplement
Labeling
NDA218160 ↗
Nov 20, 2025RETEVMO
SELPERCATINIB
LLY
Eli Lilly and Co
New drug (NDA), supplement
Labeling
NDA213246 ↗
Nov 20, 2025RETEVMO
SELPERCATINIB
LLY
Eli Lilly and Co
New drug (NDA), supplement
Efficacy
NDA213246 ↗
Oct 28, 2025EBGLYSS
LEBRIKIZUMAB-LBKZ
LLY
Eli Lilly and Co
Biologic (BLA), supplement
Labeling
BLA761306 ↗
Oct 23, 2025OMVOH
MIRIKIZUMAB-MRKZ
LLY
Eli Lilly and Co
Biologic (BLA), supplement
Labeling
BLA761279 ↗
Sep 25, 2025INLURIYO
IMLUNESTRANT TOSYLATE
LLY
Eli Lilly and Co
New drug (NDA)
Type 1 - New Molecular Entity
NDA218881 ↗
Sep 25, 2025ZEPBOUND, ZEPBOUND KWIKPEN
TIRZEPATIDE
LLY
Eli Lilly and Co
New drug (NDA), supplement
Labeling
NDA217806 ↗
Sep 25, 2025MOUNJARO, MOUNJARO KWIKPEN
TIRZEPATIDE
LLY
Eli Lilly and Co
New drug (NDA), supplement
Labeling
NDA215866 ↗
Aug 19, 2025CYRAMZA
RAMUCIRUMAB
LLY
Eli Lilly and Co
Biologic (BLA), supplement
Labeling
BLA125477 ↗
Jul 9, 2025HUMATROPE
SOMATROPIN
LLY
Lilly
Biologic (BLA), supplement
Labeling
BLA019640 ↗
Jul 1, 2025KISUNLA
DONANEMAB-AZBT
LLY
Eli Lilly Co
Biologic (BLA), supplement
Efficacy
BLA761248 ↗
May 28, 2025MOUNJARO, MOUNJARO KWIKPEN
TIRZEPATIDE
LLY
Eli Lilly and Co
New drug (NDA), supplement
Labeling
NDA215866 ↗
May 28, 2025TRULICITY
DULAGLUTIDE
LLY
Eli Lilly and Co
Biologic (BLA), supplement
Labeling
BLA125469 ↗
May 22, 2025EBGLYSS
LEBRIKIZUMAB-LBKZ
LLY
Eli Lilly and Co
Biologic (BLA), supplement
Labeling
BLA761306 ↗
May 7, 2025HUMALOG KWIKPEN
INSULIN LISPRO RECOMBINANT
LLY
Eli Lilly and Co
Biologic (BLA), supplement
Labeling
BLA205747 ↗
Letter or label ↗
May 7, 2025INSULIN LISPRO, INSULIN LISPRO JUNIOR KWIKPEN, INSULIN LISP…
INSULIN LISPRO RECOMBINANT
LLY
Lilly
Biologic (BLA), supplement
Labeling
BLA020563 ↗
Letter or label ↗
Apr 7, 2025CYRAMZA
RAMUCIRUMAB
LLY
Eli Lilly and Co
Biologic (BLA), supplement
Efficacy
BLA125477 ↗
Letter or label ↗
Mar 21, 2025EMGALITY
GALCANEZUMAB-GNLM
LLY
Eli Lilly and Co
Biologic (BLA), supplement
Labeling
BLA761063 ↗
Feb 27, 2025VERZENIO
ABEMACICLIB
LLY
Eli Lilly and Co
New drug (NDA), supplement
Labeling
NDA208716 ↗
Feb 7, 2025ZEPBOUND, ZEPBOUND KWIKPEN
TIRZEPATIDE
LLY
Eli Lilly and Co
New drug (NDA), supplement
Labeling
NDA217806 ↗
Jan 27, 2025CYRAMZA
RAMUCIRUMAB
LLY
Eli Lilly and Co
Biologic (BLA), supplement
Efficacy
BLA125477 ↗
Letter or label ↗
Jan 22, 2025SYMBYAX
FLUOXETINE HYDROCHLORIDE; OLANZAPINE
LLY
Lilly
New drug (NDA), supplement
Labeling
NDA021520 ↗
Letter or label ↗
Jan 15, 2025OMVOH
MIRIKIZUMAB-MRKZ
LLY
Eli Lilly and Co
Biologic (BLA), supplement
Efficacy
BLA761279 ↗

The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:02 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates